Abstract |
Plasma retinol levels and toxicity were evaluated in thirteen metastatic breast cancer patients treated orally with high-dose (300,000 I.U./day) retinyl acetate in combination with oral tamoxifen. Following the first dose of the drug, there was a drop of plasma retinol concentrations followed by a recovery to the pre-treatment levels and by a further increase to reach a plateau six to eight hours after drug administration. During the first two months of treatment cumulative increase of plasma retinol was seen, and long-term systemic concentrations in the +50-60% range level were maintained by the treatment. The toxicity observed was acceptable and included gastrointestinal symptoms, skin toxicity and headache. These toxicities could be related to the long-term increase of retinol systemic concentrations. We concluded that the daily dose of 300,000 I.U. retinyl acetate can be administered to cancer patients over a period of several months, is well tolerated and yields a substantial increase of systemic retinol.
|
Authors | M Resasco, L Canobbio, F Trave, G Valenti, A Mazzoni, G Canti, F Boccardo, A Nicolin |
Journal | Anticancer research
(Anticancer Res)
1988 Nov-Dec
Vol. 8
Issue 6
Pg. 1319-23
ISSN: 0250-7005 [Print] Greece |
PMID | 3218964
(Publication Type: Journal Article)
|
Chemical References |
- Diterpenes
- Retinyl Esters
- Tamoxifen
- Vitamin A
- retinol acetate
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Breast Neoplasms
(blood, drug therapy)
- Diterpenes
- Female
- Humans
- Retinyl Esters
- Tamoxifen
(administration & dosage, therapeutic use)
- Vitamin A
(administration & dosage, adverse effects, analogs & derivatives, blood, therapeutic use)
|